Theratechnologies

Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded on October 19, 1993 and is headquartered in Montréal, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

100% of patients expressed satisfaction with treatment experience

Theratechnologies Announces Results From Two Posters Presented at ACTHIV 2021 Annual Meeting Highlighting Positive Patient Experience With Trogarzo®

MONTREAL, May 18, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will participate in a virtual fireside chat hosted by Edward Nash at Canaccord Genuity on Thursday, May 20, 2021 at 2:00 p.m. ET.

Theratechnologies to Participate in Virtual Fireside Chat With Canaccord Genuity on May 20, 2021

MONTREAL, May 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today held its annual meeting of shareholders.

Announcements in Conjunction With Theratechnologies Annual Meeting

Theratechnologies Inc. (THTX) CEO Paul Levesque on Q1 2021 Results - Earnings Call Transcript

MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the first quarter ended February 28, 2021 (Q1 Fiscal 2021).

Theratechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer will present at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 10:30 a.m. ET.

Theratechnologies to Present at the Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the first quarter of fiscal 2021 ended February 28, 2021 on Wednesday, April 14, 2021.

Theratechnologies to Announce Financial Results for Its First Quarter Fiscal 2021

TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone TH1902 anti-tumor post-treatment effect persists longer than with docetaxel alone

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types

MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition of two new senior resources to support the growth and development of its commercial and pipeline assets. Effective today, Theratechnologies is pleased to welcome Mr. John Leasure as Global Commercial Officer and Mr. Peter Kowal as Vice President, HIV-U.S. Commercial Operations.

Theratechnologies Announces Two Strategic Hires to Support its Commercial and Pipeline Assets

MONTREAL, March 24, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors.

Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors

Theratechnologies (THTX) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Theratechnologies (THTX) Enters Overbought Territory

Data presented at ENDO 2021 Data presented at ENDO 2021

Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation

MONTREAL, March 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new positive pre-clinical data on TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors, will be presented in two e-posters during AACR Annual Meeting 2021.

Theratechnologies Announces Two E-Posters on TH1902 To Be Presented at American Association for Cancer Research (AACR) Annual Meeting 2021

Theratechnologies Inc. (THTX) CEO Paul Levesque on Q4 2020 Results - Earnings Call Transcript

MONTREAL, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually March 9 – 10, 2021.

Theratechnologies to Present at the H.C. Wainwright Global Life Sciences Conference

Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively Record Q4 and FY2020 revenues of $19.1 million and $66.1 million, respectively

Theratechnologies Announces Fourth Quarter and Fiscal Year 2020 Financial Results

MONTREAL, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced, today that it will issue its financial results for the fourth quarter and fiscal year ended November 30, 2020 on Thursday, February 25, 2021.

Theratechnologies to Announce Financial Results for Fourth Quarter and Fiscal Year 2020

The FDA has designated Fast Track status to Theratechnologies Inc's (NASDAQ: THTX) TH1902 as a single agent for treating patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

Theratechnologies' Peptide Conjugate Candidate For Solid Tumor Nabs Priority Review Tag In US, Shares Rally

MONTREAL, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Food and Drug Administration (FDA) has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.

Theratechnologies' Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation for the Treatment of Sortilin-expressing Cancers

MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the closing of its previously-announced bought-deal public offering (the “Offering”) pursuant to which the Company issued 16,727,900 units of the Company (the “Units”) at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit) (the “Offering Price”) for aggregate gross proceeds to the Company of US$46,001,725 (equivalent to approximately C$58,714,929), including the full exercise of the over-allotment option to purchase an additional 2,181,900 Units at the Offering Price.

Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET.

Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities

I n addition to ovarian and triple-negative breast cancers , TH1902 shows pre-clinical in vivo efficacy in colorectal, pancreatic, melanoma and endometrial cancers

Theratechnologies Announces New Findings for its Lead Investigational Compound TH1902 for the Treatment of Several Additional Cancers

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1 and 2, 2020.

News for Theratechnologies Stock (THTX)